Sunshine Heart rallies as Thoratec falls

Sunshine Heart (SSH) moves 2.7% higher in premarket trading.

Investors are likely reacting to the NEJM and JHLT manuscripts which warn of device exchanges linked to thrombus occurring with HeartMate II (THOR) devices.

SSH's C-Pulse system treats clinical symptoms associated with Class III and ambulatory Class IV heart failure.

THOR is now -10% premarket

For more on the journal manuscripts, THOR, and HTWR, see here and here

Comments (1)
  • mister-ugly
    , contributor
    Comments (357) | Send Message
    interesting CRT Capital put a buy on HTWR as it rose 2.89%: While Forbes alerted that "deadly problems arise with a live saving device" pumps we're not working, and causing blood clots in Heartmates by THOR. Cleveland Clinic noted problems almost two years ago. All this information released in a one week span. I have no position in HTWR presently and in past HTWR bought out another company which I had an interest in. I do have an interest in SSH and no position in THOR.
    1 Dec 2013, 10:13 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs